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ABSTRACT The 2-aminopyridine MMV048 was the ﬁrst drug candidate inhibiting Plas-
modium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter
clinical development. In an effort to identify the next generation of PI4K inhibitors, the
series was optimized to improve properties such as solubility and antiplasmodial po-
tency across the parasite life cycle, leading to the 2-aminopyrazine UCT943. The com-
pound displayed higher asexual blood stage, transmission-blocking, and liver stage activ-
ities than MMV048 and was more potent against resistant Plasmodium falciparum and
Plasmodium vivax clinical isolates. Excellent in vitro antiplasmodial activity translated into
high efﬁcacy in Plasmodium berghei and humanized P. falciparum NOD-scid IL-2Rnull
mouse models. The high passive permeability and high aqueous solubility of UCT943,
combined with low to moderate in vivo intrinsic clearance, resulted in sustained expo-
sure and high bioavailability in preclinical species. In addition, the predicted human
dose for a curative single administration using monkey and dog pharmacokinetics was
low, ranging from 50 to 80 mg. As a next-generation Plasmodium PI4K inhibitor,
UCT943, based on the combined preclinical data, has the potential to form part of a
single-exposure radical cure and prophylaxis (SERCaP) to treat, prevent, and block the
transmission of malaria.
KEYWORDS 1-phosphatidylinositol 4-kinase inhibitor, absorption, distribution
metabolism, excretion, pharmacokinetic/pharmacodynamic modeling, Plasmodium
spp., drug discovery, human dose prediction, in vivo efﬁcacy, malaria,
pharmacokinetics
Malaria, an infectious disease transmitted to people through the bite of femaleAnophelesmosquitoes infected with Plasmodium falciparum or Plasmodium vivax, still
afﬂicts millions of people, with almost 90% of cases on the African continent. Even though
the number of malaria cases has fallen globally from an estimated 237 million cases in 2010
to 216 million cases in 2016, malaria still causes 445,000 deaths per year, 99% of which are
due to P. falciparum in Africa (1). Parasite resistance against currently recommended
artemisinin-based combination therapies (2, 3) is a concern, and antimalarial drugs with a
novel mode of action are urgently needed. We previously reported the identiﬁcation of the
2-aminopyridine compound MMV390048 (also known as MMV048), which is efﬁcacious in
vivo against all measurable Plasmodium life cycle stages except hypnozoites (4). MMV048
acts through the inhibition of Plasmodium phosphatidylinositol 4-kinase (PI4K) and is the
ﬁrst and sole agent with this mode of action that has entered clinical development. PI4K
was reported as a target for Plasmodium in 2013 with inhibition by other compound classes
(5). The low aqueous solubility associated with MMV048 in biorelevant medium was
identiﬁed as one of the issues to address in the next generation of PI4K inhibitors along
with improved potency. Toward this goal, a scaffold change from the 2-aminopyridine to
the 2-aminopyrazine core with concomitant introduction of aqueous solubilizing groups
delivered analogues with a better developability proﬁle with respect to improved physi-
cochemical properties, as well as a signiﬁcant improvement in potency across the parasite
life cycle. Improved aqueous solubility was optimally achieved through the incorporation of
a piperazinylamide group on the phenyl ring at the 5-position of the 2-aminopyrazine
scaffold, leading to UCT943 (Fig. 1). This compound, among other attributes, showed
potent in vitro activity against multiple stages of the parasite life cycle and excellent in vivo
efﬁcacy in the Plasmodium berghei and P. falciparum NSG (NOD-scid IL-2Rnull) mouse
models (6). In order to assess the potential of UCT943 as a follow-on compound to MMV048
and a preclinical antimalarial candidate, physicochemical, parasitological, and pharmaco-
logical proﬁling was undertaken. Furthermore, extensive drug metabolism and pharmaco-
kinetics (DMPK) proﬁling was carried out in order to facilitate the prediction of human
pharmacokinetic (PK) parameters and the efﬁcacious single dose in humans. The results are
reported here.
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RESULTS AND DISCUSSION
Rationale for optimization of MMV048 resulting in UCT943. Although MMV048
showed good potency against asexual blood stage parasites, there was room for
improvement with respect to activity against liver and the transmissible gametocyte
stage parasites (4).
During ﬁrst-in-human (FIH) studies, MMV048 showed high variability in exposure,
which was attributed to low solubility. Intensive and time-consuming formulation work
had to be carried out in order to identify a new formulation with a more consistent and
3-fold greater exposure (www.mmv.org/newsroom/interviews/mmv048-0).
To avoid such developability issues in the future, improved solubility, pH dependent
and in biorelevant medium, was identiﬁed as the main differentiating factor in
follow-on compounds. Thus, chemical modiﬁcations to MMV048 were made in such a
way as to incorporate solubility-enhancing moieties. In this regard, the methyl sulfonyl
group of MMV048 was replaced by a water-solubilizing piperazinyl carboxamide on the
phenyl ring at the 5-position of the 2-aminopyrazine core to deliver UCT943 (6).
Improvements in asexual blood stage and liver stage activities were achieved by
replacing the 2-aminopyridine ring with a 2-aminopyrazine ring, which also maintained
good potency against gametocytes (6). One key objective of this study was ﬁrst to
determine if these improvements would translate into better in vivo efﬁcacy in the P.
falciparum-infected NSG mouse model and, accordingly, a low predicted human dose.
In vitro antiplasmodial activity. The biological target of the clinical candidate
MMV048 was identiﬁed to be Plasmodium phosphatidylinositol 4-kinase (PI4K) through
resistant-mutant generation, sequencing, and pulldown experiments (4). Plasmodium
PI4K has recently been identiﬁed as a new and promising drug target, which is present
at all life cycle stages of the P. falciparum and P. vivax parasites (5). UCT943 inhibits the
P. vivax PI4K (PvPI4K) enzyme with a 50% inhibitory concentration (IC50) of 23 nM. When
tested against a 5-fold-resistant P. falciparum strain generated against MMV0489, due
to a mutated pi4k (pfpi4k) locus (4), UCT943 displayed a 6-fold shift in IC50 relative to
that of the parental Dd2 strain (14 nM relative to 2.2 nM) (see Table S2 in the
supplemental material). When resistance was selected for in Dd2-B2 using UCT943,
pfpi4k mutants with a 4- or 9-fold IC50 shift were obtained (Table S3). These mutants
carried the G1309V or Y1342F mutation, respectively, located in the same region of pi4k
as MMV048-selected mutations reported elsewhere (4). Resistance selection studies
indicated a minimum required inoculum of 107 Dd2 parasites for resistance to emerge,
which is similar to that of MMV048 (4). In comparison, IC50 shifts were within 2-fold
when UCT943 was tested against strains containing mutated loci in either pfcytB,
pfdhodh, pfatp4, or pfcarl. These data indicate that UCT943 and MMV048 have the same
molecular targets and that, similarly to MMV048, UCT943 is expected to have
transmission-blocking and liver stage activities. Importantly, UCT943 maintained high in
vitro selectivity (200-fold) for the parasite PvPI4K versus the human PI4K isozyme
(IC50 of PI4K, 5.4 M), inhibition of which is linked to immunosuppressive effects (7).
UCT943 was one of the most potent compounds assessed in the 2-aminopyrazine
chemical series (6), with IC50s of 5.4 and 4.7 nM against NF54 and K1 P. falciparum strains,
FIG 1 Structures of UCT943 and MMV048.
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respectively, values that are 5- to 6-fold more active than the IC50s of the clinical candidate
MMV048 (4) (Fig. 2). In addition, UCT943 was equally active against the drug-sensitive NF54
strain and multidrug-resistant strains, with IC50s ranging from 4 to 7 nM, thus suggesting
that cross-resistance with existing antimalarials is a low risk (Table S1). UCT943 primarily
exhibited blood stage activity against schizonts (Table S5), which correlates with a slow rate
of kill, as determined in the in vitro parasite reduction ratio (PRR) assay (lag phase, 48 h; log
PRR, 2.5 at 10 the 50% effective concentration [EC50] in strain 3D7) and in the in vitro
speed assay (Table S5). As expected, the killing rate proﬁle of UCT943 was similar to that of
MMV048 (lag phase, 48 h; log PRR, 2.7) (4). When tested against P. falciparum clinical isolates
of the Ivory Coast, UCT943 exhibited potent activity (2 to 15 nM) (Table S6). The potency of
UCT943 against clinical isolates from Papua, Indonesia, was signiﬁcantly higher than that of
MMV048 in P. vivax and in P. falciparum (median UCT943 IC50s of 14 nM and 29 nM for P.
vivax and P. falciparum, respectively [P  0.012]; median MMV048 IC50s of 93 nM and 202
nM, respectively [P 0.001]) (Fig. 2 and Table S7). Interestingly, both compounds displayed
higher potency against P. vivax than against P. falciparum, a trend that was also observed
for another PI4K inhibitor, KDU691, albeit to a lesser extent (5).
When tested against other stages of the parasite life cycle (Fig. 2), UCT943 was 2 to
50 times more potent than MMV048 (4). UCT943 was potent against early-stage (90%
stages I to III) and late-stage (95% stages IV and V) gametocytes (IC50s of 134 nM and
66 nM, respectively) and inhibited the formation of both male and female gametes (IC50
of 80 nM) in a dual-gamete formation assay (DGFA). The latter activity translated into
transmission-blocking activity (target candidate proﬁle TCP5 as deﬁned by Burrows
et al. [8]) in a standard membrane feeding assay (SMFA), with an IC50 of 96 nM (9),
equivalent to that of MMV048 (Fig. 2). In-depth clinical PK/pharmacodynamic (PD)
FIG 2 Antiplasmodial activity of UCT943 compared to that of MMV048 against different stages of the parasite life cycle (values indicate
IC50s in nanomolar; black, UCT943; brown, MMV048). Values were determined in a standard membrane feeding assay, indirect mode
(footnote symbol a) (9), or prophylactic assay (footnote symbol b). Pf, P. falciparum; Pb, P. berghei; Pv, P. vivax; R/T/S, ring/trophozoite/
schizont. (Reused with permission from MMV.)
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investigations would be needed to determine doses that would afford coverage for
both blood stage and transmission-blocking activities. A single drug with both activities
would be a valuable addition to the arsenal of antimalarial medicines. UCT943 also
exhibits better in vitro liver stage activity than MMV048 (potentially addressing TCP3
and TCP4 [8]), targeting schizonts in vitro (IC50s of100 nM and10 nM in P. vivax and
Plasmodium cynomolgi, respectively, when tested prophylactically, and of 0.92 nM in P.
berghei), as well as inhibiting the formation of hypnozoites (IC50s of 100 nM and 10
nM in P. vivax and P. cynomolgi, respectively, when tested prophylactically) (Fig. 2). The
parasitophorous vacuole membrane protein UIS4 becomes internalized in MMV048-
treated P. berghei HepG2 cultures, a morphology associated with in vitro liver stage
parasite clearance (4). Though UCT943 was not evaluated for such morphological
changes, its activity against schizonts offers prospects for improved prophylactic liver
stage activity relative to that of MMV048.
Physicochemical characterization. UCT943 was stable in the solid state over a
period of 18 months and was chemically stable at 20°C in solutions of dimethyl
sulfoxide (DMSO), water (pH 6.2), and buffers (pH 2 and pH 7.4) over 6 days.
The piperazinylamide group accounts for the signiﬁcantly lower measured lipophi-
licity of UCT943 (distribution coefﬁcient, logD, of 0.27) than that of MMV048 (logD of
2.6). This, combined with a pKa of 7.5, results in higher measured solubility in aqueous
medium than that of MMV048 across a range of physiologically relevant pHs up to 6.5,
where the compound is protonated (Table 1). The compound was also highly soluble
in simulated gastric ﬂuid (SGF; pH 1.8), fed-state simulated intestinal ﬂuid (FeSSIF; pH
5.0), and fasted-state simulated intestinal ﬂuid (FaSSIF; pH 6.5) media (1.5 mg/ml),
predictive of a good dissolution in the gastrointestinal tract. The pH-dependent solu-
bility proﬁle of UCT943 in aqueous medium was typical of a weak base with higher
solubility at pH below the pKa, i.e., 7.5 (Fig. 3). UCT943 exhibited high permeability
across Caco-2 cells in both directions (apparent permeability, basolateral to apical
direction, Papp B¡A 25 106 cm/s; Papp A¡B 28 106 cm/s) without appreciable
efﬂux (efﬂux ratio of 0.93) (Table 2). With high FaSSIF solubility and high permeability,
UCT943 can be classiﬁed as a developability classiﬁcation system (DCS) class I com-
pound, which bodes well for a much more favorable development pathway compared
to that of MMV048, which was classiﬁed as DCS class II (Fig. 4) (10). The high solubility
and permeability of UCT943, along with its potent anti-Plasmodium activity against all
stages of the parasite life cycle (see the section “Rationale for optimization of MMV048
resulting in UCT943”), triggered comprehensive DMPK proﬁling toward determining its
potential for preclinical development.
TABLE 1 Physicochemical properties of UCT943 and MMV048
Property
Value for the property (SD)
UCT943 MMV048
Mol wt (g/mol) 427.4 393.4
LogD (pH 7.4) 0.27 (0.01) 2.6 (0.03)
pKa (measured) 7.45 (0.05) 4.0 (0.07)
Thermodynamic solubility (g/ml) by:a
pH
2.0 3,000 740
4.0 49
6.0 110 4.2 (pH 6.5)
8.0 31 4.0 (pH 7.4)
10.0 8.3
Mediumb
SGF (pH 1.8) 5,900
FaSSIF (pH 6.5) 1,500 14.4
FeSSIF (pH 5.0) 1,900 28.3 (pH 5.8)
aSingle determination.
bSGF, simulated gastric ﬂuid; FaSSIF, fasted-state simulated intestinal ﬂuid; FeSSIF, fed-state simulated
intestinal ﬂuid.
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In vitro and in vivo metabolism studies. There was no evidence of chemical
instability for UCT943 in human, dog, rat, or mouse blood or plasma. The compound
was moderately bound to plasma proteins with little species differentiation (unbound
fraction [fu] in plasma, 0.10 to 0.16). It also had a greater propensity than MMV048
(blood-to-plasma partitioning ratio [B/P] of 1.0 across species) to bind or distribute in
red blood cells (RBCs) than in plasma (B/P varying from 1.5 to 2.3 across species). This
is likely due to enhanced partitioning through the acidic phospholipid bilayer of the cell
membrane due to the weakly basic piperazine moiety. The higher partitioning into
RBCs possibly contributes to a small degree to its potent in vitro and in vivo anti-
Plasmodium activity by localizing the drug where the parasite resides.
As an indicator of hepatic metabolism, UCT943 was incubated across species with
hepatocytes, liver microsomes, and liver S9 fractions (Table 2). The intrinsic clearance
(CLint) of UCT943 in both microsomes and hepatocytes was low in human, rat, and
mouse (CLint,11.6 l/min/mg in microsomes and4 l/min/106 cells in hepatocytes),
while it was moderate in dog (CLint, 28.2 l/min/mg in microsomes and 9 l/min/106
cells in hepatocytes). Additionally, no signiﬁcant metabolism (10% degradation) was
detected in the human liver S9 fraction, showing that enzymes other than cytochrome
P450s (CYPs) were not extensively involved in the metabolism of UCT943. No measur-
able inhibition was detected at 20 M against any of the CYP isoforms tested (CYP2D6,
CYP2C9, and CYP3A4/5), indicating that UCT943 has low potential for in vivo enzyme
FIG 3 Comparison of pH solubility proﬁles of MMV048 (048 Sol) and UCT943 (943 Sol). Calculated and
measured values for MMV048 (triangle) and UCT943 (square) are indicated. FaSSIF, fasted-state simulated
intestinal ﬂuid; FeSSIF, fed-state simulated intestinal ﬂuid.
TABLE 2 In vitro metabolism, protein binding, blood/plasma ratio, and plasma stability
data for UCT943a
Parameter
Value for the parameter (SD) in:
Human Dog Rat Mouse
Microsomal CLint (l/min/mg) 11.6 (0.1) 28.2 (0.5) 11.6 (0.2) 11.6 (0.7)
Hepatocyte CLint (l/min/106 cells)b 2 9 4 4
Hepatocyte predicted EHb 0.2 0.65 0.23 0.2
fu microsomes 0.15 (0.01) 0.50 (0.04) 0.45 (0.05) 0.47 (0.04)
fu plasma 0.17 (0.009) 0.10 (0.007) 0.15 (0.009) 0.10 (0.02)
Blood/plasma ratio 1.5 (0.1) 2.3 (0.1) 2.1 (0.2) 1.9 (0.2)
Plasma stability (after 240 min) (%)b 97 95 97 102
aPermeability across Caco-2 cells in both directions, Papp B¡A and Papp A¡B, was determined as (25 	 5) 
106 cm/s and (28 	 2)  106 cm/s, respectively.
bSingle determination.
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inhibition and that adverse drug-drug interactions through oxidative metabolism are
likely to be minimal.
Metabolite identiﬁcation was performed in vitro using liver microsomes and hepa-
tocytes, as well as in vivo by analyzing the collected blood samples from mouse PK
experiments (Fig. 5a). In vitro, liver microsomes and hepatocytes gave a complementary
FIG 4 Ranking of UCT943 and MMV048 in the developability classiﬁcation system (DCS) (10). Peff,
effective permeability.
FIG 5 (a) Proposed metabolic pathway of UCT943 in microsomes (mouse, rat, and human) and hepatocytes and in vivo in mice. (b) Metabolite proﬁles of UCT943
in liver microsomes and hepatocytes and in mice. LM, liver microsomes; Hp, hepatocytes; H, human; R, rat; M, mouse; D, dog.
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picture, both showing the major biotransformation pathway occurring on the piper-
azinylamide moiety (Fig. 5b). UCT943 was mainly metabolized into an oxidation me-
tabolite (P
16), which was further dehydrogenated into two metabolites, P
14 (I and
II) in nonhuman species. Further biotransformation on the piperazine ring gave me-
tabolites P26 (piperazine ring cleavage) and P
28. The formation of the carboxylic
acid derivative by hydrolysis of the piperazinylamide moiety (P68) was more easily
detected in hepatocytes and in vivo in mice than in liver microsomes, presumably due
to the higher concentration of the enzymes responsible for this particular biotransfor-
mation. The contribution of these metabolites to the activity of the parent UCT943 is
under investigation. Notably, the P68 metabolite, resulting from the hydrolysis of the
carboxamide, showed high activity, albeit lower than that of the parent, with IC50s of
33 nM and 32 nM against P. falciparum NF54 and K1 strains, respectively (6).
Pharmacokinetic studies. When administered intravenously, the blood clearance
(CLb) of UCT943 was low in mice, rats, and dogs (Table 3), with a value of less than 20%
of hepatic blood ﬂow (11), and very low in monkeys, with a blood CL of5% of hepatic
blood ﬂow, which is consistent with the high in vitro metabolic stability. The plasma
volume of distribution at steady state (Vss) was high in all species (Vss of 7.1 to 13.1
liters/kg), suggesting that the compound extensively distributes and accumulates in
organ tissues. This would be expected for a basic compound due to partitioning into
cell membranes by association with acidic phospholipids (12). As a consequence of the
low CL and high Vss, half-lives (t1/2s) were long, ranging from 6 h in mice to 29 h in
monkeys. When dosed orally in mice and dogs, UCT943 was rapidly absorbed (time of
maximum concentration, Tmax, of 3 h), while absorption in rats and monkeys was
slower, with maximum concentrations (Cmaxs) reached after 12 h and 7 h, respectively
(Fig. 6). Oral bioavailability was high across all species, ranging from 66% to 98%. The
good oral bioavailability and the long t1/2 of UCT943 across species are encouraging in
terms of the goal of achieving a single-dose treatment and cure for malaria, which
would boost patient compliance in resource-limited regions of the world, where the
medical infrastructure is not sufﬁcient. If these PK properties are conﬁrmed in humans,
UCT943 could thus be a potential combination partner in a single-exposure radical cure
and prophylaxis (SERCaP) treatment, as proposed by the Medicines for Malaria Venture
(MMV) (8).
In vivo efﬁcacy studies. When dosed at 10 mg/kg per os (p.o.), UCT943 reduced
parasitemia by99.9% in the mouse P. berghei infection model and cured all mice, with
30 mean survival days (MSD). At 3 mg/kg p.o., no complete cure was achieved, and
MSD was 10 days (6), albeit parasitemia was reduced by 99%. The resulting 90%
effective dose (ED90) was 1.0 mg/kg p.o. in the P. berghei infection model. In the P.
falciparum-infected NSG mouse model (Fig. S1), UCT943 was 2-fold more potent than
MMV048, with an ED90 of 0.25 mg/kg for UCT943 and 0.57 mg/kg for MMV048 (4). PK
TABLE 3 In vivo pharmacokinetic parameters for UCT943 across mouse, rat, dog, and monkey species calculated from noncompartmental
analysis
Parameterb
Value for the parameter by species and route of drug administration (SD)
Mouse Rat Dog Monkey
i.v. p.o. i.v. p.o. i.v. p.o. i.v. p.o.
Dose (mg/kg) 5 20 5 20 2 10 2 10
t1/2 (h) 6.4 (0.7) 5.7 (0) 7.4 (0.6) 5.3 (0.3) 13.0 16.1 28.6 34.6
Plasma Vss (liters/kg) 13.1 (1.1)a 11.5 (2.1)a 7.1 (0.9) 8.7 (1.0)
CLb (ml/min/kg) 12.6 (2.4) 9.5 (1.6) 3.3 (0.6)a 2.0 (0.3)a
CLp (ml/min/kg) 24.0 (4.6)a 20.0 (3.4)a 7.5 (1.2) 3.9 (0.6)
Plasma AUC0-∞ (min · M) 497 (8.5)a 1,310 (202)a 725 (109)a 2,843 (480)a 634 (89) 2,335 (754) 1,192 (164) 4,745 (761)
Plasma Cmax (M) 1.2 (0.2)a 1.7 (0.3)a 2.4 (0.2)a 2.1 (0.7)a 1.0 (0.1) 2.3 (0.4) 1.5 (0.03) 2.1 (0.4)
Tmax (h) 4.0 (3.6) 12.0 2.3 (1.5) 7.0 (1.7)
F (%) 66 (10) 98 (4.9) 74 (23.7) 80 (12.8)
aBlood values were scaled to plasma values using B/P ratios of 1.9, 2.1, 2.3, and 2.0 for mice, rats, dogs, and monkeys, respectively.
bCLb, blood clearance; CLp, plasma clearance; AUC0-∞, area under the concentration-time curve from 0 h to inﬁnity; F, bioavailability.
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data showed that the exposure of UCT943 was dose dependent (6). As PK/PD relation-
ships in the humanized NSG mouse model have been found to be predictive of the
induced blood stage malaria (IBSM) model in human volunteers (13), we used the NSG
mouse efﬁcacy data for human dose prediction (see the next section).
Prediction of human pharmacokinetics and efﬁcacious single dose by PK/PD
modeling. (i) Allometric scaling. The slope used to predict plasma CL by allometric
FIG 6 Whole-blood concentration–versus–time proﬁles following i.v. (left panels) and oral (p.o.) (right panels)
administration of UCT943 to nonfasted male BALB/c mice (a and b), fasted male Sprague Dawley rats (c and d),
fasted male beagle dogs (e and f), and fasted female Cynomolgus monkeys (g and h). 642943, MMV642943
(UCT943). Each line represents results for an individual animal.
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scaling was close to 0.75 (0.73), while the slope used to predict plasma Vss was close to
1 (0.90), as expected for metabolic processes and volumes, respectively (14) (Fig. 7). The
predicted human plasma Vss was moderately large (6.3 liters/kg), and the predicted
human plasma CL was low (0.20 liters/h/kg), as shown in Table 4. When converted using
the B/P ratio of 1.5, the predicted human blood clearance was 0.10 liters/h/kg, i.e., less
than 10% of liver blood ﬂow (11). The predicted t1/2 in humans was 27 h which,
together with a long mean residence time of 32 h, suggests that the compound will be
a long-duration antimalarial agent.
(ii) Estimation of MPC in blood in the P. falciparum-infected NSG mouse model.
From the PK/PD model (Fig. S2 and S3), the compound-speciﬁc PD parameters EC50 and
maximal kill rate constant (Kkill) were estimated to be 3.7 ng/ml and 0.060/h, respec-
tively. The minimum parasiticidal concentration in blood (MPCb), calculated using the
EC50, was 7.4 ng/ml in NSG mouse blood and 5.2 ng/ml in human blood (Table 4), after
correction for P. falciparum-infected NSG mouse and human B/P partitioning data (2.8
and 1.5, respectively). The MPC in plasma (MPCp) used for human dose prediction was
therefore 2.6 ng/ml. The in vivo parasite reduction ratio (PRR) of 48 h predicted by the
PK/PD model (log PRR of 1.25) correlated closely to the in vitro moderate killing proﬁle
(log PRR of 2.5), conﬁrming UCT943 as a slow-acting antimalarial compound in this
model.
(iii) Prediction of human pharmacokinetic parameters and efﬁcacious dose. The
human PK proﬁles modeled in the Berkeley Madonna program predicted a single
human dose of 50 to 80 mg, based on dog and monkey data, respectively, in order to
maintain the plasma concentrations above the predicted therapeutic level (that is, the
plasma MPC of 2.6 ng/ml) for 8 days (i.e., four asexual parasite cycles) (Fig. S4 and S5).
In this model, a single administration of the efﬁcacious dose to maintain plasma
FIG 7 Allometric plots for UCT943 plasma clearance (left) and plasma volume of distribution (right).
TABLE 4 Predicted human PK parameters for UCT943 from modeling
Parametera Value for UCT943
Plasma Vss (liters/kg) 6.3
Plasma CL (liters/h/kg) 0.20
MRT (h) 32
MPC (ng/ml)
Plasma 2.6
Blood 5.2
ka (h1) 0.25
F (%) 80
Single dose (mg)b 50–80
t1/2 (h) 27
Plasma AUC (ng · h/ml) 4,213–8,223
Plasma Cmax (ng/ml) 234–358
aMPC, minimum parasiticidal concentration; F, bioavailability.
bPredicted single dose to achieve 8 days above the MPC.
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concentrations above the MPCp for 8 days resulted in an area under the curve (AUC) of
4,213 to 8,223 ng · h/ml and a predicted Cmax of 234 to 358 ng/ml, based on monkey
and dog, respectively. The low predicted dose is particularly encouraging since it leaves
a generous margin for potential dose increases in case the predicted value is under-
estimated or the dose increase is deemed desirable to prevent the development of
resistance or to ensure activity against other malaria species (including P. vivax) (see the
section above on the rationale for optimization of MMV048).
In vitro cytotoxicity, cardiotoxicity, and genotoxicity. Cytotoxicity, assessed
against four mammalian cell lines, was found to be low, with a UCT943 selectivity index
(SI) greater than 2,200 relative to the IC50 in NF54 and greater than 170-fold against the
highest IC50 in P. falciparum clinical isolates (Table 5). The UCT943 SI is equivalent to or
greater than that of MMV048. Relative to the predicted upper unbound Cmax (0.13 M)
for the human efﬁcacious plasma exposure, a 90-fold margin is thereby predicted and
is sufﬁciently high to warrant progression into in vivo preclinical toxicology studies.
The safety margins over cardiotoxicity risk were largely improved with UCT943
compared to those with MMV048 (SIs in Table 5). The hERG (ether-à-go-go-related
gene) IC50 of 10 M corresponds to an 80-fold margin relative to the predicted
therapeutic unbound Cmax exposure for efﬁcacy, which indicates a low risk of QT
interval prolongation at therapeutic exposures. The margins to potential safety issues
associated with potential off-target activities at other ion channels (NaV1.5, CaV1.2, and
KV1.5) are even higher (Table 5).
Genotoxicity was evaluated using the Ames and mouse micronucleus tests, in which
UCT943 tested negative at the highest concentrations (Table 5), suggesting that the
compound does not have the potential to result in back-mutation of a defective gene
to recover its function (Ames test) (15) and does not have the ability to induce the
formation of micronuclei during cell division as a consequence of genetic damage
(micronucleus assay) (16).
In vivo G6PD hemolysis. In the search for new antimalarial compounds, it is
essential to develop drugs which do not pose a red blood cell hemolysis risk to patients
with glucose-6-phosphate dehydrogenase (G6PD) deﬁciency (8). When assessed for in
vivo hemolytic toxicity in NOD-SCID mice engrafted with A G6PD-deﬁcient human red
blood cells (huRBCs), UCT943 showed day 7 huRBC levels comparable to those of mice
treated with the vehicle control, these levels being signiﬁcantly higher than those of
the positive control primaquine (25 mg/kg/day). This indicates that UCT943 does not
induce hemolytic toxicity at doses of either 1.5 or 10 mg/kg/day (Fig. S6), which is
higher than the ED90 of 0.25 mg/kg in the P. falciparum NSG model of infection.
Assessment of other markers of hemolysis, including spleen weight and mouse reticu-
TABLE 5 Cytotoxicity and cardiotoxicity data for UCT943 and MMV048a
Toxicity in cell line or ion channel
CC50 (SI), Mb
UCT943 lowest SIcMMV048 UCT943
Cytotoxicity
CHO cells 17 (3,148) 298
Vero cells 113 (20,926) 1,982
HepG2 cells 10 (357) 13 (2,407) 225
L6 cells 251 (8,964) 12 (2,222) 211
Cardiotoxicity
hERG (Kv11.1) 11 (393) 10 [6.4–15.9] (1,870) 177
NaV1.5 100 (3,571) 33 (6,111) 579
CaV1.2 16 (571) 33 (6,111) 579
KV1.5 33 (6,111) 579
aBoth MMV048 and UCT943 were negative for genotoxicity by the Ames test and micronucleus assay.
bCC50, 50% cytotoxic concentration; SI, selectivity index. SI is calculated as the CC50/IC50 of strain NF54,
where IC50 is the 50% inhibitory concentration. SI values are given as fold change.
cLowest selectivity index against clinical isolates. The lowest SI is calculated as the CC50/maximum IC50 of the
P. falciparum clinical isolates.
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locyte levels, also supports the ﬁnding that UCT943 did not induce hemolytic toxicity
(Fig. S7a and b).
Conclusion. UCT943 was optimized for antiplasmodial activity from a series of
2-aminopyrazines by structural modiﬁcation of the clinical candidate MMV048, an
inhibitor of an essential Plasmodium enzyme, PI4K. Incorporation of a piperazinylamide
group resulted in enhanced water solubility while maintaining high permeability, both
of which are key parameters for a good developability proﬁle and for achieving high
drug exposure. This, combined with minimal in vitro metabolism in liver subcellular
fractions and in hepatocytes, translated into low clearance, sustained exposure, and
high bioavailability in preclinical species. UCT943 was potent against all stages of the
Plasmodium parasite life cycle, as well as against resistant P. falciparum and P. vivax
clinical isolates. The 5-fold increase in in vitro antiplasmodial activity of UCT943
compared to that of MMV048 translated into excellent efﬁcacy in the P. berghei mouse
model and improved efﬁcacy in the humanized P. falciparum mouse model. UCT943
was found to be a slow-acting, long-duration antimalarial compound, similar to quin-
oline antimalarials such as meﬂoquine. The predicted human single dose using monkey
and dog pharmacokinetics was low, ranging from 50 to 80 mg, which offers consider-
able potential for the drug candidate. The high safety margins over cytotoxicity and
cardiac toxicity highlighted here are much larger than the predicted human therapeutic
exposure, which is promising. Based on the data presented, UCT943 displays asexual
blood stage, transmission-blocking, and liver stage activities and thus has the potential
to form part of a single-exposure radical cure and prophylaxis (SERCaP) treatment of
uncomplicated malaria. This breadth of activity offers considerable ﬂexibility with
respect to treatment options and target product proﬁles (TPPs) that might be ad-
dressed and has contributed to the selection of UCT943 for preclinical development as
a follow-on compound to MMV048.
MATERIALS AND METHODS
Chemistry. UCT943 was synthesized in seven steps from commercially available 2-aminopyrazine, as
previously described (6).
In vitro antiplasmodial activity. (i) Asexual blood stage assays. (a) Cross-resistance against ﬁeld
isolates. UCT943 was tested using the [3H]hypoxanthine incorporation assay (17, 18) against a panel of
drug-sensitive and drug-resistant P. falciparum strains (see Table S1 in the supplemental material), as well
as against a panel of resistant P. falciparum clones generated in the laboratory of David Fidock (Columbia
University, USA) (Table S2).
(b) In vitro P. falciparum resistance generation to UCT943 and PI4K gene sequencing. The
generation of UCT943-resistant P. falciparum clones was performed as described elsewhere (4) (Table S4).
(c) Ex vivo assay against resistant P. falciparum clinical isolates from Côte d’Ivoire. Drug
susceptibility of P. falciparum isolates from Côte d’Ivoire, West Africa, was measured using incorporation
of SYBR green into the parasite’s DNA as described before (19). The drug plates contained 10 serial
concentrations of the antimalarials, with a maximum concentration of 1,170 nM for UCT943.
(d) Ex vivo schizont maturation drug susceptibility assay against P. vivax and P. falciparum
clinical isolates. Drug susceptibility of P. vivax and P. falciparum isolates from Papua, Indonesia, was
measured using a modiﬁed schizont maturation assay as described previously (19). The drug plates
contained 11 serial concentrations of the antimalarials, with maximum concentrations of 2,993 nM for
chloroquine, 1,029 nM for piperaquine, 338 nM for meﬂoquine, 49 nM for artesunate, and 297 nM for
UCT943.
(ii) Liver stage assays. (a) P. berghei liver stage assay. Plasmodium berghei luciferase sporozoites
were obtained by dissection of infected Anopheles stephensi mosquito salivary glands. A sporozoite
invasion assay was performed as described in Le Manach et al. (6) using the rodent parasite P. berghei,
which is able to infect human hepatocarcinoma HepG2-A16-CD81EGFP cells (20, 21).
(b) P. cynomolgi liver stage assay. Primary rhesus hepatocytes were infected in vitro with P.
cynomolgi sporozoites, and the drug assays were performed as previously reported by Zeeman et al. (22).
(c) P. vivax liver stage assay. A P. vivax liver stage assay was implemented in human hepatocytes
infected in vitro with P. vivax sporozoites, according to the protocol described in Sattabongkot et al. (23).
(iii) Gametocyte assays. In vitro gametocytocidal activity was determined using luciferase reporter
lines speciﬁcally enabling screening against early-stage gametocytes (90% stages I to III) and late-stage
gametocytes (95% stages IV and V) as per Reader et al. (24). Methylene blue (5 M) and MMV048 (5
M) were routinely included as controls.
(iv) P. falciparum DGFA. Transmission-blocking activity of UCT943 was assessed in a dual-gamete
formation assay (DGFA), which utilizes a dual readout that individually and simultaneously reports on the
functional viability of male and female mature stage V gametocytes, as per Ruecker et al. (25).
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Physicochemical properties. The pKa of UCT943 was determined by potentiometric titration as
described previously (26). Solubility was measured after 24 h of incubation of solid material with medium
at 37°C with residual solids checked by X-ray power diffraction (XRPD). Media included ﬁve pH buffers
(pH 2.0, 4.0, 6.0, 8.0, and 10.0) and three biorelevant media: simulated gastric ﬂuid (SGF; pH 1.8),
fasted-state simulated intestinal ﬂuid (FaSSIF; pH 6.5), and fed-state simulated intestinal ﬂuid (FeSSIF; pH
5.0). Analyses were done by high-performance liquid chromatography (HPLC) (Waters Xbridge C18
column, 150 by 4.6 mm, 3-m particle size) at 40°C with a mobile phase of 0.1% triﬂuoroacetic acid (TFA)
in water and 0.1% TFA in acetonitrile, with UV detection (220 nm; reference, 500 nm).
In vitro metabolism studies. Metabolic stability of UCT943 (1 M) was assessed in human, dog, rat,
and mouse liver microsomes using a ﬁve-point assay and liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) as described by Gibhard et al. (27). Metabolic stability (1 M) was also evaluated
with cryopreserved hepatocytes from the same species (1  106 viable cells/ml), as described in Phillips
et al. (28). Hepatic extraction ratios (EHs) were calculated using physiologically based scaling factors as
previously described (29).
Binding to plasma proteins and microsomal proteins (0.5 mg/ml) was determined by ultracentrifu-
gation with LC-MS analysis as described in Coteron et al. (30) and Gibhard et al. (27), respectively.
Permeability was determined across Caco-2 monolayers in both apical-to-basolateral and basolateral-
to-apical directions using pH 7.4 in both apical and basolateral chambers, as reported in Phillips et al.
(19).
Cytochrome P450 (CYP450) inhibition studies (CYP2D6, CYP2C9, and CYP3A4/5) were carried out with
pooled human liver microsomes under the conditions described in Walsky and Obach (31). Metabolite
identiﬁcation was performed by LC-MS/MS, as described in Le Manach et al. (32), with a Phenomenex
Kinetex PFP (pentaﬂuorophenyl) column (2.1 mm by 100 mm, 2.6-m particle size) using microsomal
incubations, incubations in hepatocytes from the hepatocyte stability assay, and in vivo mouse PK
samples.
Plasma stability and whole-blood–to–plasma (B/P) partitioning ratios were determined by spiking
blood from humans (Australian Red Cross blood bank), dogs, rats, or mice with UCT943 and incubating
samples for 4 h at 37°C. During the incubation period, aliquots of blood were taken to conﬁrm stability.
At the end of the incubation period, duplicate aliquots of blood were taken, and the remaining sample
was centrifuged to collect duplicate aliquots of plasma. Concentrations in blood and the plasma fraction
of blood were measured by LC-MS, and the blood-to-plasma concentration ratio was calculated using the
mean concentration for each matrix.
Ethics statement. Animal experiments were approved by the institutional animal care and use
committees for each of the experimental sites. All studies were conducted according to the appropriate
legislation and respective institutional policies on animal use and welfare.
The human biological samples were sourced ethically, and their research use was in accord with the
terms of the informed consents.
Pharmacokinetic studies. Pharmacokinetic studies were performed in mice, rats, dogs, and mon-
keys as described in the supplemental material. For comparison of blood clearance (CLb) to hepatic blood
ﬂow, values of 90, 55, 31, 44, and 21 ml/min/kg were assumed in mice, rats, dogs, monkeys, and humans,
respectively (11).
In vivo efﬁcacy studies. In vivo efﬁcacy studies were conducted in the P. berghei and P. falciparum
NOD-scid IL-2Rnull (NSG) models as described previously (6, 33; see also the supplemental material).
Prediction of human pharmacokinetics and efﬁcacious single dose by pharmacokinetic/phar-
macodynamic (PK/PD) modeling. (i) Allometric scaling. The calculation of human plasma clearance
(CLp) and of human plasma volume of distribution at steady state (Vss) for UCT943 was carried out by a
hybrid approach to allometric interspecies scaling (mouse, rat, dog, and monkey) of in vivo plasma CLp
and Vss (34). After logarithmic/logarithmic transformation, the parameters were ﬁtted to the equation
log(y)  log(a) 
 b · log(BW), where BW is body weight and a and b are the allometric coefﬁcient and
exponent, respectively. Body weights of 0.025, 0.3, 5, 10, and 70 kg were used for mice, rats, monkeys,
dogs, and humans, respectively. The mean residence time (MRT) was calculated from the predicted
human plasma Vss divided by the predicted human plasma CLp.
(ii) PK/PD analysis in the P. falciparum-infected NSGmouse model to predict MPC. Blood PK data
from P. falciparum-infected NSG mice were ﬁrst ﬁtted to a one-compartment model with ﬁrst-order
absorption and elimination. The predicted PK proﬁles were used to run a direct effect (DE) PK/PD model
using Phoenix WinNonlin (Certara, Princeton, NJ) in order to determine the minimum parasiticidal
concentration (MPC) of UCT943 (Equations S1 and S2 in the supplemental material).
(iii) Simulation of human PK proﬁles for human dose prediction. Dog and monkey data were
used to predict human PK since higher species allow more extensive blood sampling to explore blood
or plasma concentration against time curves in detail. Intravenous (i.v.) and oral (p.o.) time course proﬁles
were normalized in PKSolver (Excel) for preclinical species and Wajima transformed (35). The absorption
rate constant (ka), and the bioavailability (F) estimates were obtained from PKSolver using the Wajima-
transformed data. Human p.o. PK parameters were predicted in Berkeley Madonna (University of
California, Berkeley, CA) using the Wajima-transformed PK data, the human PK parameters obtained from
allometric scaling as described above, and the ka and F estimates to have the drug concentration above
the MPC for 8 days. The single dose required to maintain the human plasma concentration above the
MPC for 8 days (see the previous paragraph) was determined through simulation using the human p.o.
PK proﬁles with Berkeley Madonna.
In vitro cytotoxicity, cardiotoxicity, and genotoxicity. (i) Cytotoxicity. In vitro cytotoxicity of
UCT943 was tested against L6 cells using the alamarBlue assay and against Chinese hamster ovarian
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(CHO), Vero, and HepG2 cells, using an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide] assay (36, 37).
(ii) Cardiotoxicity. UCT943 was tested for inhibition of the human ether-à-go-go-related gene
(hERG) K
 channel (Kv11.1), human Kv1.5 K
 channel, and human voltage-gated sodium channel Nav1.5
using IonWorks patch clamp electrophysiology (38) and for inhibition of the human Cav1.2 calcium
channel (cardiac L-type) using a ﬂuorescence Ca2
 assay. For all assays, 50% cytotoxic concentrations
(CC50s) were determined from 8-point dose-response curves generated using 3-fold serial dilutions from
the maximum ﬁnal assay concentration.
(iii) Genotoxicity. (a) Ames. UCT943 was assessed for mutagenic toxicity by measuring its ability to
induce reverse mutations in a Salmonella enterica serovar Typhimurium-Escherichia coli/microsome plate
incorporation assay (15, 39). Maximum concentrations were 5,000 g per plate.
(b) Micronucleus. UCT943 capability to induce clastogenicity/aneugenicity in CHO-WBL cells was
determined by measuring the extent of micronucleus formation with and without exogenous metabolic
activation (Aroclor 1254-induced rat liver S9). The maximum concentration was 500 g/ml.
In vivo G6PD hemolysis. In vivo hemolytic toxicity was assessed in NOD-SCID mice engrafted with
A glucose-6-phosphate dehydrogenase (G6PD)-deﬁcient human red blood cells (huRBCs) as described
in Rochford et al. (40) following a 4-day treatment regimen at dose levels of 1.5 and 10 mg/kg/day given
orally.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.00012-18.
SUPPLEMENTAL FILE 1, DOCX ﬁle, 0.5 MB.
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